A Cautionary Tale of Confidence vs Reality: Elizabeth Holmes

Elizabeth Holmes once reminisced, “I still have a notebook with a complete design for a time machine that I created when I must have been, like, 7. The wonderful thing about the way I was raised is that no one ever told me that I couldn’t do those things.” This childhood memory, which she cited as evidence of her early brilliance and exceptionalism, in reality, mirrors the core issues at Theranos. Although she refers to the time machine as an invention, it’s crucial to note that imagining an intricate time machine’s controls as a child, detailed as they might be, does not equate to a legitimate invention in reality. True invention requires applying existing or at least theoretically possible technology to build something functional. This distinction, often overlooked in a society where confidence and self-esteem are sometimes emphasized over actual competence, could have been a pivotal lesson in Holmes’ upbringing. The statement, “no one ever told me that I couldn’t do those things,” points to a missed opportunity during her formative years to learn the value of feasible goals and the limits of imagination versus reality. I think in hindsight it’s clear this may not have been such a “wonderful thing” and it foreshadows what occurred at Theranos.

Holmes’ unwavering conviction in her childhood creativity, viewed as a marker of exceptionalism, reflects a deeper issue that became evident in her leadership at Theranos. She was either unable or unwilling to acknowledge the impracticality of her ambitious ideas, a stance that reveals a classic case of the Dunning-Kruger effect. Her lack of expertise in biotechnology blinded her to the limitations of her ambitions. Holmes genuinely believed she was an inventor, a belief she successfully sold to some of the world’s most influential figures, despite it being fundamentally flawed.

Viewing Elizabeth Holmes not as a classic conwoman, but rather as someone profoundly ignorant and deluded about her capabilities and the feasibility of her ideas, presents a more nuanced understanding of her situation. This interpretation challenges the common perception of her as a calculated fraudster, suggesting instead that she was deeply misled by her own unfounded beliefs. However, this is far from an excuse; it represents a significant failing on her part. This viewpoint aligns with Steven Pinker’s observations on the consequences of unearned self-esteem, particularly its implications for violence in society. Pinker’s insights seem applicable to Holmes’ case, as her unwavering belief in Theranos, in the face of its glaring impracticalities, highlights a profound overconfidence not grounded in reality.

Holmes’ ability to attract the support of powerful individuals was often speculated to be influenced by her charisma and a societal desire to promote gender equality. Some of these influential figures possibly viewed her in a granddaughter-like manner, which could have played a role in their willingness to support and mentor her. This dynamic, while intended to foster gender diversity in Silicon Valley, had unintended consequences. Holmes first deceived herself and then used her confidence and certainty to spread that deception to others.

Her misinterpretation of the “fake it until you make it” philosophy, which went far beyond mere optimism or self-assurance, had significant consequences. Holmes attempted to emulate visionary figures like Steve Jobs, adopting not only their style but also their aura of confidence. However, she failed to appreciate the underlying substance and genuine innovation that drove their success. Her approach neglected the importance of real, viable technological advancements and ethical considerations, which are crucial in a field as critical as healthcare. This oversight exemplifies how an overreliance on appearance and bravado, without the backing of tangible results and ethical integrity, can lead to disastrous outcomes.

Rather than advancing the cause for women in technology and entrepreneurship, Elizabeth Holmes’ approach at Theranos has inadvertently erected significant barriers. Her actions have led to increased scrutiny and skepticism toward qualified women in these fields, casting a long shadow over their endeavors. This unintended consequence of Holmes’ high-profile failure has made it more challenging for women to secure funding, gain trust, and find mentorship in a sector already marked by gender disparity. The ripple effect of her downfall has extended beyond Theranos, potentially affecting the perception of women’s leadership and innovation capabilities. Her story, while initially seen as a beacon of female achievement in a male-dominated industry, has regrettably ended up reinforcing some of the biases and obstacles that women in tech strive to overcome. The damage to their prospects, as a result, may someday heal. While not necessarily irrevocable, it certainly sets a precedent that requires considerable effort and time to reverse.

The etymology of “Theranos,” a portmanteau combining “therapy” and “diagnosis,” inverts the essential healthcare sequence where diagnosis must logically precede therapy. This reversal in the company’s name not only deviates from standard medical practice but also subtly underscores a fundamental misunderstanding of the healthcare process. It reflects a lack of attention to detail and a flawed understanding of the healthcare sector that Holmes aimed to revolutionize, symbolizing the core misalignments within Theranos and highlighting the disregard for the critical procedural and ethical standards in medical practice.

Holmes’ clung-to conviction about her perceived exceptionalism was precisely what led to her ultimate conviction.